Presentation is loading. Please wait.

Presentation is loading. Please wait.

(A) Distribution of dMMR proteins in the entire cohort and per tumour type. (A) Distribution of dMMR proteins in the entire cohort and per tumour type.

Published byLeo Mathijs Janssens Modified over 5 years ago

Similar presentations

Presentation on theme: "(A) Distribution of dMMR proteins in the entire cohort and per tumour type. (A) Distribution of dMMR proteins in the entire cohort and per tumour type."— Presentation transcript:

1 (A) Distribution of dMMR proteins in the entire cohort and per tumour type.
(A) Distribution of dMMR proteins in the entire cohort and per tumour type. (B) Representative examples of MMR immunohistochemistry in CRC and EMC. Indicated are negative and positive tumours in rows for each MMR protein in columns. In negative tumours, note positive stromal cells and lymphocytic infiltrates (positive endogenous control). For all pictures, original magnification ×200. CRC, colorectal carcinoma; dMMR, mismatch repair deficient; EMC, endometrial carcinoma. Elena Fountzilas et al. ESMO Open 2019;4:e000474 Copyright © European Society for Medical Oncology. All rights reserved.

Download ppt "(A) Distribution of dMMR proteins in the entire cohort and per tumour type. (A) Distribution of dMMR proteins in the entire cohort and per tumour type."

Similar presentations

(A) Programmed cell death ligand-1 (PD-L1) expression score was significantly higher in pulmonary adenocarcinomas with grade G2/G3 differentiation as compared.

(A) Programmed cell death ligand-1 (PD-L1) expression score was significantly higher in pulmonary adenocarcinomas with grade G2/G3 differentiation as compared.
Representative hematoxylin-eosin stained (HE) sections demonstrating immune checkpoint inhibition-related colitis representative HE sections demonstrating.

Representative hematoxylin-eosin stained (HE) sections demonstrating immune checkpoint inhibition-related colitis representative HE sections demonstrating.
Immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH) analysis of MET and KRAS. For IHC, the specific MET antibody (Met (D1C2) XP Rabbit.

Immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH) analysis of MET and KRAS. For IHC, the specific MET antibody (Met (D1C2) XP Rabbit.
The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.

The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.
Mean density of CD8+ and Foxp3+ lymphocytes in tumour infiltrate before (pre-TPF) and after (post-TPF) induction chemotherapy, (A) Patients’ tumours with.

Mean density of CD8+ and Foxp3+ lymphocytes in tumour infiltrate before (pre-TPF) and after (post-TPF) induction chemotherapy, (A) Patients’ tumours with.
Immunohistochemistry of CD8 (A and B) and PD-L1 (C–F).

Immunohistochemistry of CD8 (A and B) and PD-L1 (C–F).
Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.

Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.
(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.

(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.
Progesterone receptor nuclear morphology patterns in breast cancer.

Progesterone receptor nuclear morphology patterns in breast cancer.
Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.

Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.
Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. (A)

Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. (A)
Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.

Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.
Mismatch repair immunohistochemistry (MMR IHC).

Mismatch repair immunohistochemistry (MMR IHC).
Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.

Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.
Waterfall plot of the best per cent change from baseline in SLD of target lesions in 33 patients. Waterfall plot of the best per cent change from baseline.

Waterfall plot of the best per cent change from baseline in SLD of target lesions in 33 patients. Waterfall plot of the best per cent change from baseline.
Flow chart of the used methodology adapted from Moher et al

Flow chart of the used methodology adapted from Moher et al
Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different treatments for the same therapeutic.

Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different treatments for the same therapeutic.
Detection rate for EGFR mutations in cfDNA.

Detection rate for EGFR mutations in cfDNA.
Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.
The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.

The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.

Similar presentations

Ads by Google